
MediciNova fell 5.0% from $1.41 to $1.34, behind the S&P 500's +10.0%. Its worst day was Sep 28 (−18.6%), and its low came Jun 12 at $1.23.
Nov 17, 2025 – Nov 17, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
MediciNova shares rose 12.0%, while the S&P 500 rose 0.0%.
+12.0% · S&P 500 0.0%
EPS of $-0.05 beat the $-0.08 estimate on $151,739.00 revenue.
−0.7% · S&P 500 −1.0%
Story events cover the past 12 months · Times ET
MediciNova shares rose 12.2%, while the S&P 500 fell 1.4%.
+12.2% · S&P 500 −1.4%
EPS of $-0.05 beat the $-0.06 estimate on $186,984.00 revenue.
−1.4% · S&P 500 −1.2%
MediciNova closed at its lowest level of the year, 12.8% below where the year started.
−3.9% · S&P 500 +0.5%
EPS of $-0.05 beat the $-0.06 estimate on $458,439.00 revenue (est. $90,000.00).
0.0% · S&P 500 −0.2%
MediciNova shares rose 13.3%, while the S&P 500 rose 1.0%.
+13.3% · S&P 500 +1.0%
MediciNova closed at its highest level of the year, 144.7% above where the year started.
+36.9%, the year's best day, on 7M shares, the year's heaviest volume · S&P 500 +0.9%
Study OverviewMN-001-NATG-202 was a randomized, double-blind, placebo-controlled study designed to evaluate the efficacy, safety, and tolerability of MN-001 in 40 patients with NAFLD and hypertriglyceridemia associated
−18.6%, the year's worst day · S&P 500 −0.7%
EPS of $-0.06 beat the $-0.06 estimate on $138,555.00 revenue (est. $70,000.00).
−0.4% · S&P 500 −0.4%
Where it ended: a close of $1.34 on Nov 17, 2026. Up next: Q4 2026 earnings on Feb 19, 2027 (EPS est. $-0.08, revenue est. $46,664.00).
Nothing in the past 12 months.
All MNOV dividend historyReplay the year: the line draws itself and stops at each of the 10 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for MNOV and SPY from Benzinga historical bars. Not investment advice.